...
首页> 外文期刊>Resuscitation. >Adrenaline for out-of-hospital cardiac arrest resuscitation: A systematic review and meta-analysis of randomized controlled trials
【24h】

Adrenaline for out-of-hospital cardiac arrest resuscitation: A systematic review and meta-analysis of randomized controlled trials

机译:肾上腺素用于院外心脏骤停复苏的系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: The evidence for adrenaline in out-of-hospital cardiac arrest (OHCA) resuscitation is inconclusive. We systematically reviewed the efficacy of adrenaline for adult OHCA. Methods: We searched in MEDLINE, EMBASE, and Cochrane Library from inception to July 2013 for randomized controlled trials (RCTs) evaluating standard dose adrenaline (SDA) to placebo, high dose adrenaline (HDA), or vasopressin (alone or combination) in adult OHCA patients. Meta-analyses were performed using random effects modeling. Subgroup analyses were performed stratified by cardiac rhythm and by number of drug doses. The primary outcome was survival to discharge and the secondary outcomes were return of spontaneous circulation (ROSC), survival to admission, and neurological outcome. Results: Fourteen RCTs (n=12,246) met inclusion criteria: one compared SDA to placebo (n=534), six compared SDA to HDA (n=6174), six compared SDA to an adrenaline/vasopressin combination (n=5202), and one compared SDA to vasopressin alone (n=336). There was no survival to discharge or neurological outcome differences in any comparison group, including subgroup analyses. SDA showed improved ROSC (RR 2.80, 95%CI 1.78-4.41, p0.001) and survival to admission (RR 1.95, 95%CI 1.34-2.84, p0.001) compared to placebo. SDA showed decreased ROSC (RR 0.85, 95%CI 0.75-0.97, p=0.02; I2=48%) and survival to admission (RR 0.87, 95%CI 0.76-1.00, p=0.049; I2=34%) compared to HDA. There were no differences in outcomes between SDA and vasopressin alone or in combination with adrenaline. Conclusions: There was no benefit of adrenaline in survival to discharge or neurological outcomes. There were improved rates of survival to admission and ROSC with SDA over placebo and HDA over SDA.
机译:简介:院外心脏骤停(OHCA)复苏中肾上腺素的证据尚无定论。我们系统地审查了肾上腺素对成人OHCA的疗效。方法:从开始到2013年7月,我们在MEDLINE,EMBASE和Cochrane库中搜索了评估成人的标准剂量肾上腺素(SDA)与安慰剂,高剂量肾上腺素(HDA)或血管加压素(单独或联合使用)的随机对照试验(RCT) OHCA患者。使用随机效应模型进行荟萃分析。按心律和药物剂量分层进行亚组分析。主要结局是出院生存,次要结局是自发循环(ROSC)恢复,入院生存率和神经系统结局。结果:14个RCT(n = 12,246)符合纳入标准:1个SDA与安慰剂比较(n = 534),6个SDA与HDA比较(n = 6174),6个SDA与肾上腺素/加压素组合(n = 5202),有人将SDA与单独的加压素进行了比较(n = 336)。在任何比较组中,包括亚组分析,均无生存率或神经系统预后差异。与安慰剂相比,SDA显示出改善的ROSC(RR 2.80,95%CI 1.78-4.41,p <0.001)和入组生存率(RR 1.95,95%CI 1.34-2.84,p <0.001)。与SDA相比,SDA显示ROSC降低(RR 0.85,95%CI 0.75-0.97,p = 0.02; I2 = 48%)和入院生存率(RR 0.87,95%CI 0.76-1.00,p = 0.049; I2 = 34%) HDA。单独使用SDA和加压素或联合使用肾上腺素在结局方面无差异。结论:肾上腺素对出院或神经系统预后的生存没有益处。与安慰剂相比,SDA的入院率和ROSC生存率均高于SDA,HDA的生存率有所提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号